Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Peyvandi

Showing results (471-480 of 500) with videos related to

Pageof 50
Sort By:
Microbiology Spectrum|September 1, 2021
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in ItalyElisa Saccon, Alessandra Bandera, Mariarita Sciumè, et al.
Research and Practice in Thrombosis and Haemostasis|May 1, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial resultsAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
The Journal of Allergy and Clinical Immunology|November 21, 2020
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort studyGiorgio Bozzi, Davide Mangioni, Francesca Minoia, et al.
Research and Practice in Thrombosis and Haemostasis|December 9, 2024
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH studySyna Miri, Frits R Rosendaal, Kaan Kavakli, et al.
Research and Practice in Thrombosis and Haemostasis|December 17, 2024
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on HemostasisWolfgang Bergmeier, Silvio Antoniak, Edward M Conway, et al.
Journal of the American College of Cardiology|July 16, 2011
Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarctionDiego Ardissino, Carlo Berzuini, Piera Angelica Merlini, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 24, 2022
IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in ItalyAnnarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2024
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ABella Madan, Margareth C Ozelo, Priyanka Raheja, et al.
Pageof 50

Showing results (471-480 of 500) with videos related to

Sort By:
Pageof 50
Microbiology Spectrum|September 1, 2021
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in ItalyElisa Saccon, Alessandra Bandera, Mariarita Sciumè, et al.
Research and Practice in Thrombosis and Haemostasis|May 1, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial resultsAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
The Journal of Allergy and Clinical Immunology|November 21, 2020
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort studyGiorgio Bozzi, Davide Mangioni, Francesca Minoia, et al.
Research and Practice in Thrombosis and Haemostasis|December 9, 2024
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH studySyna Miri, Frits R Rosendaal, Kaan Kavakli, et al.
Research and Practice in Thrombosis and Haemostasis|December 17, 2024
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on HemostasisWolfgang Bergmeier, Silvio Antoniak, Edward M Conway, et al.
Journal of the American College of Cardiology|July 16, 2011
Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarctionDiego Ardissino, Carlo Berzuini, Piera Angelica Merlini, et al.
Blood|May 2, 2020
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpuraElien Roose, An-Sofie Schelpe, Edwige Tellier, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 24, 2022
IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in ItalyAnnarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, et al.
Journal of Thrombosis and Haemostasis : JTH|April 13, 2024
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ABella Madan, Margareth C Ozelo, Priyanka Raheja, et al.
Pageof 50